ArticleFrontiers in immunology2026
Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Background: Fermentable dietary fibers, or microbiota-accessible carbohydrates (MACs), are hypothesized to enhance responsiveness to immune checkpoint blockade (ICB) therapy in breast cancer (BC) by increasing fecal short-chain fatty acid (SCFA) production. However, existing research findings have been inconsistent. Given that hormone-sensitive breast cancer is highly influenced by estrogen levels, the presence of estrogenic isoflavones in certain MAC sources may partially account for these discrepancies. Consequently, investigating the roles of isoflavones versus MACs in BC models is warranted. Methods: C57BL/6Tac mice were fed low-MAC (AIN93G), low-MAC supplemented with isoflavone genistein, high-MAC (5V5M), or high-MAC isoflavone (high-MACi; 5058D) diet to assess anti-PD1 efficacy against E0771 triple-negative breast cancer (TNBC) and 7,12-dimethylbenz[a]anthracene (DMBA)-initiated estrogen receptor α-positive (ERα Results: High-MAC diets increased fecal microbial diversity, the abundances of SCFA-producing families, and fecal SCFA levels, compared with the low-MAC diet. Anti-PD1 was effective in TNBC models with high-MAC or low-MAC diets, but responsiveness was eliminated by the inclusion of isoflavones (high MACi) or genistein (low MAC). Anti-PD1 reduced exhausted CD8 Conclusions: Our results highlight the role of diet in impacting the effectiveness of ICB therapies. Increased SCFA alone is not predictive of response to anti-PD1, but if the tumor expresses ERα or if the diet contains ERα-activating compounds, such as isoflavones, blocking ERα
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.